NASDAQ: RADXRadiopharm Theranostics Ltd Stock
$4.83+0.01 (+0.21%)
Updated Jan 23, 2025
RADX Price
$4.83
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$3.55
52 Week High
$50.82
P/E
-0.2x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$194.30k
Earnings
-$30.52M
Gross Margin
100%
Operating Margin
-15,053.04%
Profit Margin
-15,300%
Debt to Equity
1.59
Operating Cash Flow
-$15M
Beta
-1.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RADX's potential to beat the market
- RADX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RADX
RankedUnranked of 556
RankedUnranked of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.14 | A | |
| $122.48 | A | |
| $5.98 | A |
Be the first to know about important RADX news, forecast changes, insider trades & much more!
RADX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RADX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RADX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RADX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RADX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RADX due diligence checks available for Premium users.
Valuation
RADX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
-205.94x
Market
30.03x
RADX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RADX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RADX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.0M
Liabilities
$29.8M
Debt to equity
1.59
RADX's short-term assets ($14.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RADX's long-term liabilities ($17.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RADX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RADX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Radiopharm Theranostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.